Johnson & Johnson ($JNJ) is Expected to Lead Competitors with an Ad Spend Bump of 4.6% or More than $2 Billion

June 22, 2015

Johnson & Johnson’s Ethicon’s Gynecare mesh victims, Johnson & Johnson DePuy Synthes hip victims, and Johnson & Johnson Janssen Pharmaceutical Risperdal victims awaiting settlements from injury will be happy to know that Johnson & Johnson ($JNJ) is expected to lead competitors with an ad spend bump of 4.6% for total advertising spending reaching over $2 billion for 2016.  FiercePharma Marketing

var _gaq = _gaq || []; _gaq.push(['_setAccount', 'UA-36077937-2']); _gaq.push(['_trackPageview']);

(function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })();

// ]]>

// ]]>BOYCOTT Johnson & Johnson until Executives Held Accountable